The FY2025 (Dec) proxy of Verastem names 17 peer companies for pay. Among Verastem and these peers, CEO pay was the lowest of 6 and total shareholder return was 5th highest of 6.
6th highest of 6in Verastem and its pay peers, FY2025 (Dec) by CEO pay:
$2.3M$33.3M
5th highest of 6in Verastem and its pay peers, FY2025 (Dec) by total shareholder return:
$84$1,020
Pay peer group, FY2025 (Dec) proxy
| Scholar Rock Holding | ||
| Cogent Biosciences | ||
| Compass Therapeutics | ||
| Kura Oncology | ||
| Olema Pharmaceuticals | ||
| Acrivon Therapeutics, Inc. | Not disclosed | Not disclosed |
| Actinium Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Aura Biosciences | Not disclosed | Not disclosed |
| Cardiff Oncology | Not disclosed | Not disclosed |
| Celcuity | Not disclosed | Not disclosed |
| Cullinan Oncology, Inc. | Not disclosed | Not disclosed |
| Leap Therapeutics, Inc. | Not disclosed | Not disclosed |
| Lian Bio | Not disclosed | Not disclosed |
| MEI Pharma, Inc. | Not disclosed | Not disclosed |
| Syros Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Terns Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| iTeos Therapeutics, Inc. | Not disclosed | Not disclosed |
17 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.